Plain-English translation of NCT06906822 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combined with can help patients with advanced melanoma whose disease has progressed despite previous immunotherapy treatment. The medication works by targeting a protein found in melanoma cells and also strengthens the immune system's anti-tumor response. The study is enrolling about 60 patients to measure how well this two-drug combination works and how safe it is.
Many patients with advanced melanoma respond well to immune-boosting medications initially, but eventually their cancer stops responding and begins growing again. There is currently a gap in treatment options for these patients, so researchers are testing whether adding this medication could help by attacking melanoma cells in a new way while also boosting the immune system's continued effectiveness.
You would receive the two medications as part of your regular clinic visits— as an intravenous infusion and as an injection. Your cancer would be monitored with imaging scans and blood tests at regular intervals to see how well the treatment is working and to watch for side effects. The study is currently not recruiting new participants, but eligible patients would be followed throughout their treatment to measure both how their cancer responds and how well they tolerate the medications.
AI-generated summary from trial data · Sep 20, 2026 · Not medical advice
Spain